A computationally designed antigen eliciting broad humoral responses against SARS-CoV-2 and related sarbecoviruses
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part
Is influenza B/Yamagata extinct and what public health implications could this have? An updated literature review and comprehensive assessment of global surveillance databases
Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan
CD8+ T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear.
CYP19A1 mediates severe SARS-CoV-2 disease outcome in males
International Pediatric COVID-19 Severity Over the Course of the Pandemic
This cohort study suggested that while intensive care unit admission decreased over the course of the pandemic in all age groups, ventilatory and oxygen support did not decrease over time in children aged younger than 5 years.
Co-evolution of immunity and seasonal influenza viruses
Seasonal influenza viruses cause recurring global epidemics by continually evolving to escape host immunity. The viral constraints and host immune responses that limit and drive the evolution of these viruses are increasingly well understood.
The SARS-CoV-2 Spike Protein Mutation Explorer: using an interactive application to improve the public understanding of SARS-CoV-2 variants of concern
The rapid evolution of SARS-CoV-2 resulted in variations in the spike that enhanced transmissibility or weakened vaccine protection.
TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry
SARS-CoV-2 is associated with broad tissue tropism, a characteristic often determined by the availability of entry receptors on host cells.
Dispersal patterns and influence of air travel during the global expansion of SARS-CoV-2 variants of concern
Long Covid: clues about causes
This investigated the monocyte and inflammatory profiles of individuals who were hospitalised with COVID-19 during the acute phase and the convalescent period.
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
This study demonstrates durable yet compartmentalised nasal IgA and plasma antibody responses to SARSCoV-2 after infection and subsequent vaccination.